Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses some of the challenges that come with conducting clinical trials in the treatment of patients with bladder cancer.
Geoffrey Sklar, MD
Advertisement
Articles by Geoffrey Sklar, MD
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.
Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the role of nivolumab in the treatment of patients with bladder cancer.
Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.
Advertisement
Latest Updated Articles
Dr. Sklar on the Role of Nivolumab in Bladder CancerPublished: January 10th 2017 | Updated:
Dr. Sklar on Immunotherapy Potential in Bladder CancerPublished: January 28th 2017 | Updated:
Dr. Sklar on Challenges With Clinical Trials in Bladder CancerPublished: February 7th 2017 | Updated:
Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder CancerPublished: November 5th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5